Renovacare Financials

RCAR

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2022 Currency USD FYE December

This page shows Renovacare (RCAR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Renovacare passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.02x

For every $1 of reported earnings, Renovacare generates $1.02 in operating cash flow (-$4.6M OCF vs -$4.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-843.0x

Renovacare earns $-843.0 in operating income for every $1 of interest expense (-$5.4M vs $6K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$5.4M

YoY+44.2%

Renovacare's EBITDA was -$5.4M in fiscal year 2021, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 44.2% from the prior year.

Free Cash Flow

N/A

Net Income

-$4.5M

YoY+53.2%

Renovacare reported -$4.5M in net income in fiscal year 2021. This represents an increase of 53.2% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

$2.8M

YoY-61.6%

5Y CAGR+46.8%

10Y CAGR+13.7%

Renovacare held $2.8M in cash against $0 in long-term debt as of fiscal year 2021.

Dividends Per Share

N/A

Shares Outstanding

87M

YoY+0.0%

5Y CAGR+4.5%

10Y CAGR+3.3%

Renovacare had 87M shares outstanding in fiscal year 2021. This represents an increase of 0.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$3.2M

YoY-22.5%

5Y CAGR+59.6%

10Y CAGR+56.3%

Renovacare invested $3.2M in research and development in fiscal year 2021. This represents a decrease of 22.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RCAR Income Statement

Metric	FY21	FY20	FY19	FY18	FY17	FY16
Revenue	N/A	$0	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.2M-22.5%	$4.1M+454.2%	$746K+102.2%	$369K-35.7%	$574K+85.5%	$310K
SG&A Expenses	$2.2M-60.2%	$5.5M+88.3%	$2.9M+79.6%	$1.6M-22.7%	$2.1M+33.5%	$1.6M
Operating Income	-$5.4M+44.1%	-$9.7M-162.2%	-$3.7M-83.8%	-$2.0M+25.5%	-$2.7M-42.0%	-$1.9M
Interest Expense	$6K-95.0%	$129K-61.2%	$332K+332.4%	$77K-0.6%	$77K+407.8%	$15K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M+53.2%	-$9.5M-184.3%	-$3.4M-58.3%	-$2.1M+42.5%	-$3.7M-77.6%	-$2.1M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'22	Q2'22	Q1'22	Q3'21	Q2'21	Q1'21	Q4'20	Q3'20
Revenue	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$388K+2.3%	$379K-36.4%	$596K-19.9%	$745K+5.7%	$705K-33.2%	$1.1M	N/A	$1.6M
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.3M
Operating Income	-$1.9M+11.8%	-$2.1M	N/A	-$1.7M-53.8%	-$1.1M-113.7%	-$517K	N/A	-$2.8M
Interest Expense	$2K+1.4%	$2K+600.7%	$289-87.1%	$2K-14.4%	$3K+37257.1%	$7	N/A	$25K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$400K+82.4%	-$2.3M-31.5%	-$1.7M-1.7%	-$1.7M-86.2%	-$912K-76.3%	-$517K	N/A	-$2.8M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RCAR Balance Sheet

Metric	FY21	FY20	FY19	FY18	FY17	FY16
Total Assets	$3.7M-56.5%	$8.4M-32.5%	$12.4M-20.9%	$15.7M+413.6%	$3.1M+407.3%	$603K
Current Assets	$3.4M-57.6%	$8.0M-35.1%	$12.3M-21.1%	$15.6M+435.5%	$2.9M+546.6%	$450K
Cash & Equivalents	$2.8M-61.6%	$7.4M-39.2%	$12.2M-20.9%	$15.4M+429.8%	$2.9M+595.2%	$418K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-0.9%	$1.3M+369.2%	$281K-28.5%	$393K-71.9%	$1.4M+283.5%	$364K
Current Liabilities	$1.3M+1.3%	$1.3M+359.0%	$281K-28.5%	$393K+9.3%	$359K-1.3%	$364K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.3M-66.8%	$7.1M-41.8%	$12.2M-20.7%	$15.3M+820.8%	$1.7M+595.5%	$239K
Retained Earnings	-$34.2M-15.0%	-$29.8M-47.2%	-$20.2M-19.9%	-$16.9M-14.4%	-$14.7M-33.4%	-$11.1M

Metric	Q3'22	Q2'22	Q1'22	Q3'21	Q2'21	Q1'21	Q4'20	Q3'20
Total Assets	$1.1M-26.5%	$1.4M-52.3%	$3.0M-17.6%	$3.7M-29.1%	$5.2M-20.1%	$6.4M-23.2%	$8.4M-10.6%	$9.4M
Current Assets	$1.1M-24.4%	$1.4M-49.7%	$2.8M-17.9%	$3.4M-29.7%	$4.8M-20.8%	$6.1M-23.9%	$8.0M-10.8%	$8.9M
Cash & Equivalents	$101K-58.7%	$244K-87.0%	$1.9M-34.4%	$2.8M-34.4%	$4.3M-22.6%	$5.6M-24.4%	$7.4M-14.5%	$8.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-6.5%	$2.7M+23.0%	$2.2M+67.6%	$1.3M+490.5%	$221K-71.8%	$784K-40.5%	$1.3M+63.8%	$804K
Current Liabilities	$1.7M-9.4%	$1.9M+36.1%	$1.4M+6.3%	$1.3M+502.6%	$217K-71.7%	$766K-40.5%	$1.3M+69.1%	$762K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.5M-16.3%	-$1.3M-252.9%	$821K-65.0%	$2.3M-52.4%	$4.9M-13.0%	$5.7M-20.0%	$7.1M-17.6%	$8.6M
Retained Earnings	-$38.6M-1.0%	-$38.2M-6.3%	-$36.0M-5.0%	-$34.2M-9.8%	-$31.2M-3.0%	-$30.3M-1.7%	-$29.8M-9.3%	-$27.2M

RCAR Cash Flow Statement

Metric	FY21	FY20	FY19	FY18	FY17	FY16
Operating Cash Flow	-$4.6M+3.4%	-$4.7M-47.0%	-$3.2M-58.5%	-$2.0M-21.0%	-$1.7M+6.4%	-$1.8M
Capital Expenditures	N/A	$41K	$0	N/A	N/A	$951
Free Cash Flow	N/A	-$4.8M-48.3%	-$3.2M	N/A	N/A	-$1.8M
Investing Cash Flow	N/A	-$49K	$0	N/A	N/A	-$951
Financing Cash Flow	N/A	N/A	N/A	$14.5M+248.8%	$4.2M+130.0%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'22	Q2'22	Q1'22	Q3'21	Q2'21	Q1'21	Q4'20	Q3'20
Operating Cash Flow	-$148K+90.9%	-$1.6M+8.6%	-$1.8M-210.8%	-$573K+54.7%	-$1.3M+29.9%	-$1.8M-43.5%	-$1.3M+18.6%	-$1.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$1.3M	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0+100.0%	-$41K
Financing Cash Flow	$0	$0-100.0%	$800K	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RCAR Financial Ratios

Metric	FY21	FY20	FY19	FY18	FY17	FY16
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-122.4%-8.7pp	-113.7%-86.7pp	-27.0%-13.5pp	-13.5%+107.1pp	-120.5%+223.9pp	-344.4%
Current Ratio	2.59-3.6	6.19-37.6	43.77+4.1	39.64+31.6	8.09+6.9	1.24
Debt-to-Equity	0.56+0.4	0.19+0.2	0.020.0	0.03-0.8	0.84-0.7	1.52
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'22	Q2'22	Q1'22	Q3'21	Q2'21	Q1'21	Q4'20	Q3'20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-37.9%+120.4pp	-158.3%-100.9pp	-57.4%-16.9pp	-40.5%-22.8pp	-17.7%-9.7pp	-8.0%	N/A	-30.0%
Current Ratio	0.62-0.1	0.74-1.3	2.00-0.6	2.59-19.6	22.20+14.3	7.92+1.7	6.19-5.5	11.74
Debt-to-Equity	-1.72+0.4	-2.14-4.8	2.67+2.1	0.56+0.5	0.04-0.1	0.14-0.0	0.19+0.1	0.09
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Statera Biopharma Inc STAB

$7K

Virpax Pharmaceuticals Inc VRPX

$5.7M

Novaccess Global Inc XSNX

$6K

Biostax Corp BTAX

$16K

BETTER THERAPEUTICS INC BTTX

$5K

Frequently Asked Questions

Is Renovacare profitable?

No, Renovacare (RCAR) reported a net income of -$4.5M in fiscal year 2021.

What is Renovacare's EBITDA?

Renovacare (RCAR) had EBITDA of -$5.4M in fiscal year 2021, measuring earnings before interest, taxes, depreciation, and amortization.

What is Renovacare's operating cash flow?

Renovacare (RCAR) generated -$4.6M in operating cash flow during fiscal year 2021, representing cash generated from core business activities.

What are Renovacare's total assets?

Renovacare (RCAR) had $3.7M in total assets as of fiscal year 2021, including both current and long-term assets.

How much does Renovacare spend on research and development?

Renovacare (RCAR) invested $3.2M in research and development during fiscal year 2021.

How many shares does Renovacare have outstanding?

Renovacare (RCAR) had 87M shares outstanding as of fiscal year 2021.

What is Renovacare's current ratio?

Renovacare (RCAR) had a current ratio of 2.59 as of fiscal year 2021, which is generally considered healthy.

What is Renovacare's debt-to-equity ratio?

Renovacare (RCAR) had a debt-to-equity ratio of 0.56 as of fiscal year 2021, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Renovacare's return on assets (ROA)?

Renovacare (RCAR) had a return on assets of -122.4% for fiscal year 2021, measuring how efficiently the company uses its assets to generate profit.

What is Renovacare's cash runway?

Based on fiscal year 2021 data, Renovacare (RCAR) had $2.8M in cash against an annual operating cash burn of $4.6M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Renovacare's Piotroski F-Score?

Renovacare (RCAR) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Renovacare's earnings high quality?

Renovacare (RCAR) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Renovacare cover its interest payments?

Renovacare (RCAR) has an interest coverage ratio of -843.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.